Merz Aesthetics, the world’s largest dedicated medical aesthetics business, has launched flagship products XEOMIN ® (incobotulinumtoxinA) and RADIESSE ® in China. With this expansion into the world’s ...

This is read by an automated voice. Please report any issues or inconsistencies here. Surgical rhinoplasty may be the gold standard, but now the scalpel is no longer the default. Patients today, ...

Trials designed to reflect migraine burden and patient experience Merz Therapeutics continues to build on established neurotoxin expertise Merz Therapeutics GmbH, a leading player in neurology-focused ...

“The enrollment of the first patients in the MINT trials marks an important milestone as we aim to address persistent gaps in migraine care by advancing a new neurotoxin option for patients.” MINT-E ...

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced that the first patients have been enrolled in two global Phase III clinical trials — MINT-E (NCT07018700 ...

"Despite the availability of multiple treatment options, the need remains for additional options for prevention of migraines," says Stefan König, CEO, Merz Therapeutics. "The enrollment of the first ...

A strand of Merz Pharmaceuticals’ star-studded promotion of the anti-wrinkle drug Xeomin has landed it a reprimand from the FDA. The agency sent an untitled letter after finding fault with how the ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Please provide your email address to receive an email when new articles are posted on . Xeomin is the first neurotoxin that can simultaneously treat frown lines, forehead lines and crow’s feet. Xeomin ...

When treating all 3 areas simultaneously, the maximum recommended dose is 64 Units. The Food and Drug Administration (FDA) has expanded the approval of Xeomin ® (incobotulinumtoxinA) to include ...

The new approval expands Xeomin’s indications to include horizontal forehead lines and lateral canthal lines. The FDA has approved Merz Aesthetics’ Xeomin (incobotulinumtoxinA) as the first and only ...